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W
idespreadgenetictestingformutationsinthebreastcancer
associated protein BRCA1 has revealed an unprecedented
viewoftherangeofgeneticvariabilityinthisgenethroughoutthe
human population. To date, over 1600 distinct mutations have
been uncovered within BRCA1 (collated in the Breast Cancer
Information Core Database (BIC); http://research.nhgri.nih.
gov/projects/bic). Unfortunately, eﬀorts to classify the cancer
risks associated with these mutations have been hampered by a
lack of accurate family history and clinical data linking individual
mutationstodisease.Someofthemostdiﬃcultvariantstoassess
are the missense variants. 570 distinct missense variants have
been detectedthroughout the1863 codons ofBRCA1; however,
less than 2% of these have been conclusively associated with
cancer. Intriguingly, all the disease-associated missense muta-
tions occur within two domains: the N-terminal RING domain
and the C-terminal BRCT domain, implicating these regions as
critical for the tumor suppressor function of BRCA1.
BRCA1 plays an essential rolein the responseof cells toDNA
damage, where it mediates complex protein protein interac-
tions that both regulate the cell cycle and promote DNA repair
through homologous recombination in response to DNA
damage.
1 Two domains are particularly critical in mediating
protein protein signaling events within the DNA damage
response. The BRCA1 N-terminal RING domain, bound in a
heterodimeric complex with the RING domain of BARD1, acts
as an E3 ubiquitin ligase that likely ubiquitylates as yet unde-
termined targets.
2,3 The C-terminal pair of tandem BRCT
repeats functions as a phosphopeptide binding module, selec-
tively binding partner proteins such as the DNA helicase
BACH1/FANCJ, the DNA resectioning factor CtIP, and DNA
double strand break targeting protein, Abraxas.
4,5
A number of functional and structural studies have provided
details into the mechanism of phosphopeptide recognition em-
ployedbytheBRCA1BRCTdomain.Thetwotandemrepeatsthat
make up the domain pack together in a head-to-tail manner that is
characteristicofthepackingseeninmanyotherBRCTproteinsthat
are involved in DNA damage signaling
6,7 (Figure1A).TheBRCA1
BRCT domain speciﬁcally binds phosphopeptide motifs containing
a phosphoserine and a phenylalanine residue at the þ3C - t e r m i n a l
position.
4,5 N-terminal repeat provides a shallow pocket that
recognizes the phosphoserine speciﬁcally over phosphothreonine
8
throughelectrostaticinteractionsbetweenthephosphategroupand
ligands provided by Ser1655, Lys1702, and the main-chain NH of
Gly1656
9 11 (Figure 1B). The critical phenylalanine residue is
recognized by a largely hydrophobic groove formed at the interface
between the two BRCT repeats. Interactions between the main
chain of the þ3 phenylalanine and Arg 1699 of BRCA1 help to
position the þ3 residue within this groove. BRCT repeats are a
common protein module in many proteins involved in the DNA
damage response, and the mechanism of phosphopeptide recogni-
tion employed by BRCA1 is likely conserved in several of these
other proteins.
12,13
Approximately 120 distinct missense variants have so far been
uncovered within the BRCA1 BRCT repeats through breast
cancer screening. To better understand the functional implica-
tions of these mutations, a variety of biochemical and cellular
assays,aswellascomputationalmethods,havebeendevelopedto
assess the impact of the individual mutations. Biophysical
methods have been utilized to assess the eﬀects of missense
mutations on the folding of the BRCA1 BRCT domain; however,
they often cannot be used because of an inability to produce and
purify many of the diﬀerent variants.
14 16To counter this problem,
other methods have utilized in vitro transcribed/translated proteins.
The low levels of protein produced in this way, and possibly the
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presence of protein chaperones in the reticulocite extracts used,
enabletheproductionofessentiallyanyvariant.Thefoldingstability
of variants produced in this way have been assessed by their
susceptibility to limited proteolysis,
6,17 19 and the phosphopeptide
binding activities of the variants have been assessed through
phosphopeptide pulldown studies.
11,17 Perhaps the most widely
used cellular assay for the functional integrity of the BRCA1 BRCT
domain is a transcriptional assay, derived from the ﬁnding that the
BRCA1 BRCT domain can act as a transcription activation module
in both human and yeast cells when tethered to a heterologous
DNAbindingdomain.
20,21Whiletheinvivorelevanceofthisactivity
is still uncertain, the excellent correlation between cancer risk and
the transactivation potential of the BRCA1 variant gives conﬁdence
that the transcription assay gives a meaningful readout of BRCA1
BRCTactivityinacellularcontext.
17Experimentalapproacheshave
also been complemented by studies using bioinformatics analysis
based on multiple sequence alignment,
22 structure prediction,
23,24
ormultifactoriallikelihoodmodelinginwhichavailablegeneticdata,
co-occurrence, and predictive methods are combined.
25,26
We recently completed a comprehensive analysis of the
BRCA1 BRCT missense variant set, using proteolytic mapping,
phosphopeptide binding, and transcriptional transactivation assays
to assess the functional consequences of each mutation.
17
A comparison of these results with the available family history and
clinical data for a subset of the variants revealed an excellent
correlation, suggesting that these methods might be used as part
of a cancer risk assessment strategy. The study revealed that of the
117 variants studied 42 showed little if any functional deﬁciencies,
50 showed strong functional deﬁciencies and might be associated
with an increased cancer risk, while 25 showed functional activities
intermediate between these two extremes. Several of the mutations
targeted the essential peptide-binding surface of the BRCA1 BRCT
domain.Tounderstandtheimpactofthisimportantclassofvariants
and to uncover new principles of BRCT phosphopeptide interac-
tions, we have studied each of these six variants using a quantitative
ﬂuorescence polarization assay to determine the precise eﬀect on
peptide binding of each of these variants. The structural conse-
quencesofthesevariantswere assessedthroughcrystalstructuresof
the variants, together with biophysical assessment of protein fold
stability and computationalstudies.The resultsreveal in some cases
an unexpected resilience of the phosphopeptide binding groove to
mutation and provide a better basis to predict the functional
consequences of these variants. This work provides new insight
intophosphopeptiderecognitionoftheBRCA1BRCTdomainthat
may be broadly applicable to this large family of proteins.
’EXPERIMENTAL PROCEDURES
BRCT Purification. Variants characterized in this study were
produced in pLM1-CD6
17 and were expressed in BL21-Gold
cells for 18 h at 24  C and purified as previously described.
6
Fluorescence Polarization.The fluorescent BACH1-derived
peptide was synthesized by Biomatik Corp. (Fluorescein-
GGSRSTpSPTFNK-NH2). The peptide binding affinity was
evaluated for each variant using different protein concentrations
(from 20 nM to 500 μM) with a constant concentration of
fluorescentpeptide(100nM)inareactionvolumeof20μL.The
fluorescein was excited at a wavelength of 458 nm, and the
emitted fluorescence was recorded at 538 nm with a Perkin-
ElmerEnvisionplatereader.Thepolarizationchangewasplotted
againstthelogoftheproteinconcentration,andtheKdvaluewas
derived from the resulting curve. The experiments were per-
formed in triplicate and carried out in parallel with wild-type
BRCA1 BRCT.
Circular Dichroism. Proteins were incubated at 0.1 mg mL
 1
in various guanidinium hydrochloride (GdmCl) concentrations
(50 mM sodium phosphate pH 7.5, 400 mM NaCl) for 2 h at
room temperature in duplicate. Far-UV CD spectra were re-
corded with a Jasco J-720 spectropolarimeter using a cell of
0.05cmlengthfrom250to210nm.Awavelengthstepof0.1nm
was used, and eight accumulations were carried out for each
averaged spectra. Baseline correction was performed.
Crystallization. All the crystals were obtained using the
hanging drop vapor diffusion method at room temperature.
The crystals of variants T1700A, G1656D, R1699Q, and
R1835P in their apo form were grown by mixing equal volumes
of 18 mg mL
 1 protein solution (2 μL) with well solution
(0.6 1.0 M Li2SO4 pH 7.5 8.5, 5 mM NiCl2 and 10 mM
CaCl2). Crystals appeared in the drops after 1 or 2 days and
reached their maximum size within a week. Prior to cryztalliza-
tion, E1836K variant (10 mg mL
 1) was mixed with a BACH1-
derived decapeptide (Ac-SRSTpSPTFNK-NH2) at an equimo-
lar concentration on ice. The crystallization conditions were
derivedfromClapperton etal.
9Drops werecomposedof2μLof
Figure 1. Structure of the wild-type BRCA1 BRCT domain complexed
with a phosphopeptide. (A) Cartoon representation of the tandem
BRCTrepeatsofBRCA1.The N-terminalBRCTrepeatiscoloredblue,
the C-terminal BRCT repeat is green, the inter-repeat linker is gray, and
theboundphosphopeptidederivedfromBACH1(residues986 995)is
red. The substituted residues analyzed in this study as well as the pSer
andPhe(þ3)sidechainsarehighlighted asballandsticks.(B)Close-up
view of the BRCA1 phosphopeptide binding surface. Essential BRCA1
residuesforpeptiderecognitionaswellasthepeptidepSerandPhe(þ3)
residues are represented as ball and sticks.4581 dx.doi.org/10.1021/bi2003795 |Biochemistry 2011, 50, 4579–4589
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protein solution and 2 μL of 50 mM MES pH 6.5, 26% PEG
8000, 0.15 mM (NH4)2SO4. Cocrystallization was also carried
out for the other variants under these conditions, but no crystals
were obtained.
Data Collection and Processing. Crystals were soaked in a
cryoprotectant solution (well solution complemented with
20 25% glycerol) for 1 5 min and then flash-cooled in liquid
nitrogen. All the data were recorded at 100 K on the Canadian
Light Source 08ID-1 beamline, with the exception of R1699Q
data, collected on ALS beamline 12.3.1. Diffracting frames were
indexedandintegratedusingXDS
27andwerescaledandmerged
with XSCALE and XDSCONV (Table 1).
Model Building and Refinement. The different structures
weresolvedusingthemolecularreplacementmethod(resolution
range 40 3 Å) with the software PHASER.
28 The initial search
model was a previously solved BRCA1 BRCT structure (PDB
code 1n5o). Crystals of the different apo variants (R1699Q,
T1700A, G1656D, and R1835P) grew in the space group P6122
with one molecule in the asymmetric unit. Electron density for
thesubstitutedaminoacidwasclearinthemFo DFcmaps(see
Figure S1). Refinement of the models was performed with
Phenix:
29 initial rigid-body refinement and simulated annealing
was followed by cycles of energy minimization, individual
isotropic temperature factor refinement, and TLS refinement. Five
TLS groups were defined per molecule (two for the N-BRCT, one
f o rt h el i n k e rr e g i o n ,a n dt w of o rt h eC - B R C T )u s i n gt h eT L S M D
server.
30,31 Model refinement was interspersed with sessions of
model rebuilding using the program Coot.
32 In these models, a
strong peak wasobserved in themFo  DFcFourierdifference map
between two molecules of the crystal. A nickel ion was modeled at
this position and is coordinated to residues His1805 and His1673
f r o mas y m m e t r ym a t ea sw e l la st w ow a t e rm o l e c u l e s .
6,33
The E1836K variant bound to a decapeptide crystallized in space
group C2221 with four complexes in the asymmetric unit. Model
building and reﬁnement were carried out as described above with
NCS restraints. The solvent content in this crystal is about 75%.
Poorer quality electron density was associated with chains C and D
compared to chains A and B, probably due to a poorer packing of
these chains in the crystal lattice. 4-fold NCS averaging was used to
improve maps in the areas of weak density in chains C and D
corresponding to the linker and the β3 R2a n dβ20 β30 loops.
The positive electron density of the mFo   DFc map contoured at
3σ was not good enough to completely model the side chain of
Lys1836. A simulated-annealing composite omit map was therefore
calculated with CNS 1.21,
34 and the resulting 2mFo   DFc map
clearlyindicatesdensityforthesidechainofthelysineinmonomers
A ,B ,a n dC ,b u tn o ti nm o n o m e rD( F i g u r e sS 1 E ,S 1 F ,a n dS 1 G ) .
The occupancies of the modeled peptides were reﬁned.
The geometry of the reﬁn e dm o d e l sw a sc h e c k e dw i t ht h e
molprobityserver.
35Asummaryofﬁnalmodelsstatisticsisprovided
in Table 1. The coordinates as well as structure factors have been
deposited in the Protein Data Bank (accession code 3pxa for
G1656D, 3pxb for T1700A, 3pxc for R1699Q, 3pxd for R1835P,
and 3pxe for E1836K bound to a phosphopeptide). PyMOL was
Table 1. Data and Reﬁnement Statistics
G1656D (apo) T1700A (apo) R1699Q (apo) R1835P (apo) E1836K (holo)
resolution (Å)
a 40 2.55 (2.55 2.60) 40 2.5 (2.57 2.50) 40 2.8 (2.85 2.80) 40 - 2.8(2.85-.280) 40 2.85 (2.90 2.85)
space group P6122 P6122 P6122 P6122 C2221
cell dimensions
a (Å) 114.87 114.38 114.62 114.95 115.82
b (Å) 114.87 114.38 114.62 114.95 131.05
c (Å) 122.11 122.32 122.11 121.95 180.84
completeness (%) 98.1 (99.4) 99.1 (99.8) 98.8 (99.4) 97.5 (97.6) 96.1 (73.6)
ÆI/σIæ 18.4 (3.1) 14.7 (2.6) 16.6 (3.0) 16.3 (2.2) 17.8 (2.2)
redundancy 4.8 (4.9) 3.5 (3.6) 4.7 (4.5) 3.1 (3.1) 4.4 (3.5)
Rsym 0.051 (0.479) 0.048 (0.487) 0.057 (0.502) 0.059(0.588) 0.058 (0.487)
resolution (Å) 40 2.55 40 2.5 20 2.8 40 2.8 45 2.85
no. of subunits 1 1 1 1 4
Rwork/Rfree 0.238/0.261 0.235/0.274 0.228/0.270 0.233/0.281 0.220/0.266
no. of atoms
protein 1630 1621 1614 1636 6617
peptide 0 0 0 0 198
water 29 14 13 8 16
nickel 1 1 1 1 0
sulfate 5 5 5 5 0
overall B factor (Å
2) 80.3 84.5 92.3 96.2 97.2
rmsd
bond length (Å) 0.008 0.008 0.008 0.008 0.007
bond angle (deg) 1.17 1.14 1.18 1.12 1.08
Ramachandran
b
preferred (%) 95.1 93.6 94.0 88.8 95.1
allowed (%) 4.9 4.4 6.0 10.7 4.7
disallowed (%) 0.0 0.0 0.0 0.5 0.2
aValues in parentheses refers to highest resolution shell.
bAs reported by Molprobity Server (http://molprobity.biochem.duke.edu/).4582 dx.doi.org/10.1021/bi2003795 |Biochemistry 2011, 50, 4579–4589
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used to produce all the ﬁgures (The PyMOL Molecular Graphics
System, Version 1.2r3pre, Schr€ odinger, LLC). The electrostatic
potential was calculated with APBS
36 at 300 K.
Molecular Dynamics Simulations. The crystal structure of
thewild-type BRCT domain complexedwithaphosphopeptide
9
(pdbcode1t15)andthecrystalstructureofthemissensevariants
T1700A (pdb code 3pxb) were used as starting points for the
simulations. The apo form of wild-type BRCT was simulated
from the same initial crystal structure (pdb code 1t15) in which
the phosphopeptide was removed. Each protein was first sub-
mitted to energy minimization in vacuo and was subsequently
solvated in a 10.27 nm side-lengthcubic box. The distanceof the
protein from the box walls was at least 15 nm. The system was
neutralized by addition of the appropriate number of counter-
ions, energy minimized, and equilibrated at 300 K. For each
system, four 10 ns simulations were performed with different
initialvelocities.GROMACSpackage
37wasusedtoperformMD
simulations using GROMOS 53a6 force field
38 that we modified
to contain phosphoserine residue. A constant temperature of
300 K was maintained using a Berendsen thermostat with a
couplingtimeof 0.1ps.
39ABerendsen barostat wasused tokeep
pressure at 1 bar with τp = 1.0 ps and a compressibility of 4.5  
10
 5bar
 1.
39Electrostaticinteractionswerecalculatedusingthe
particle mesh Ewald method.
40,41 Bond lengths were restrained
with the LINCS algorithm,
42 allowing a 2 fs integration step.
Coordinates of the system were saved every 1 ps.
’RESULTS
Selection of BRCA1 BRCT Missense Variants for Detailed
Structure/Function Analysis. Our previous analysis of the
structural and functional consequences of missense mutations
in the BRCA1 BRCT domain uncovered an intriguing class of
defective variants in which folding of the protein was not destabilized
as assayed by limited proteolysis.
17 We reasoned that the functional
defects associated with these variants likely were due to localized
changes of the phosphopeptide binding groove. Indeed, the variants
M1775R and M1775K fall into this class, and previous structural and
peptide binding studies revealed that conformational changes asso-
ciated with these mutations block the þ3 specificity pocket of this
surface.
11,19,43 Six additional mutations were identified in or near the
phosphopeptide binding groove: G1656D, R1699W, R1699Q,
T1700A, R1835P, and E1836K. Three missense variants, R1699Q ,
R1699W, and T1700A, were scored as “strong functional effect” in
Lee et al.’s study as they exhibited compromised activities in all the
functionalassays.Theothervariants,G1656D,R1835P,andE1836K,
Figure 2. Phosphopeptide binding and structural comparison of the wild-type BRCA1 BRCT and the G1656D variant. (A) Assessment of the
phosphopeptide binding properties of the wild-type BRCA1 BRCT (open squares) and the G1656D variant (ﬁlled squares) using a ﬂuorescence
polarization (FP) assay. (B) Cartoon overlay of wild-type (cyan) and G1656D variant (dark blue) BRCT domain. Residues involved in phosphate
recognition are represented as sticks. (C, D) Representation of electrostatic potential of wild-type (C) and G1656D variant (D) BRCT domain.
The surface of atoms that directly binds the phosphoserine is contoured (dashed lines), and the corresponding electrostatic potential is indicated in
parentheses (in kT e
 1).4583 dx.doi.org/10.1021/bi2003795 |Biochemistry 2011, 50, 4579–4589
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however, showed poor agreement between the different functional
assays, complicating assessment of the true impact of these muta-
tions. To further probe the functional defects associated with these
variants, we expressed and purified each variant for detailed struc-
tural and functional analyses.
G1656D: Addition of a Negative Charge Close to the
Phosphoserine Recognition Pocket.The Gly1656 main-chain
NH provides a critical ligand that binds the phosphate of the
target phosphopeptide. Mutation of this invariant residue to
asparticacidcouldbeexpectedtoblockphosphopeptidebinding
through a steric clash, an electrostatic repulsion of the aspartate
with the phosphate, or a conformational effect related to the
restricted main-chain geometries available to Asp compared to Gly.
The effect of this amino acid substitution on phosphopeptide
recognition was tested using a fluorescence polarization (FP) assay,
which has proven to be a highly sensitive method to assess quan-
titativechangesinBRCT phosphopeptidebindingaffinities.
33The
binding affinity of the G1656D variant to a fluorescein-labeled
Figure 3. T1700A substitution reduces phosphopeptide binding aﬃnity due to enhanced rotational freedom of a key phosphate ligand. (A) FP
experiments comparing the ability of BACH1-derived decapeptide to bind to BRCA1 BRCT wild-type (open squares) and the T1700A variant (ﬁlled
squares). (B) Superimposition of BRCA1 BRCT structure bound to a phosphopeptide (pdb entry 1t15) in gray (phosphopeptide) and blue (BRCT)
withthestructureoftheT1700Avariantinorange.(C)Ser1655χ2angulardistributionobtainedfromanMDsimulationofthewild-typeBRCA1BRCT
bound to a phosphopeptide. (D) Snapshot extracted from the wild-type BRCA1 BRCT phosphopeptide MD simulation. Important hydrogen bonds
areshownasdashedlines.ThephosphopeptideistransparentasthisSer1655conformationisalsocommonlypopulatedinasimulationoftheunbound
form of the wild-type BRCA1 BRCT. (E) Ser 1655 χ2 angular distribution obtained from the apo wild-type BRCA1 BRCT simulation (black line) and
from the T1700A variant simulation (red line). (F) Snapshot extracted from T1700A variant simulation. In this conformation, the Ser1655 side chain
hydroxyl is pointing away from the peptide-binding groove and may interact with Met1689.4584 dx.doi.org/10.1021/bi2003795 |Biochemistry 2011, 50, 4579–4589
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BACH1decapeptidewascomparedtothatofthewild-typeBRCA1
BRCTdomain(Figure2A).Surprisingly,theKdvaluesforthewild-
type and the G1656D variant are in the same narrow range, 1.2 (
0.1and1.5(0.1μM,respectively,indicatingthat thismutationhas
little if any impact on phosphopeptide binding.
To understand how this variant is able to bind phosphopep-
tide, the X-ray crystal structure of G1656D was determined at
2.55Åresolution(Table1).Theoverallfoldingisidenticaltothe
wild type, and the side chain of the aspartic residue at position
1656 could easily be modeled in the electron density of the mFo
  DFc map (Figure S1A). A comparison of this model to the
structure of wild-type BRCT bound to a phosphopeptide reveals
that the aspartic acid side chain is oriented away from the
phosphate binding pocket and does not induce any major
structural reorganization of the protein backbone (Figure 2B).
The eﬀect of the extra negative charge on the electrostatic
potential of the phosphate recognition pocket was analyzed with
the program APBS.
36 The calculation was performed using a 0.3 Å
grid over the peptide-binding surface to allow quantitative com-
parisons between the wild-type and G1656D variant. While the
electrostaticpotentialofthevariantisnegativenearthecarboxylate
group of the introduced aspartate side chain, the potential
throughout the phosphate binding pocket remains positive, and
little diﬀerence is observed in the region of the three phosphate
ligands:themainchainNHofGly/Asp1656;thehydroxylgroupof
Ser1655; and the side chain amino group of Lys1702 (Figure 2C,
D). The most signiﬁcant change in the electrostatic potential of
these ligands is observed near Ser1655 (reduction of 25%),
whereas reduction of the positive potential is less pronounced
near residue 1656 and Lys1702 (reduction of 6.1 and 8.5%,
respectively). These results suggest that the electrostatic potential
of the Ser1655 ligand may be less critical for phosphate binding,
compared to the residue 1656 and Lys1702 ligands.
T1700A: Influence of a Hydrogen Bond on the Ser 1655
Conformational Landscape. The crystal structure of wild-type
BRCA1 BRCT domain indicates that the orientation of the
Ser1655 side chain is maintained through a hydrogen bond with
Thr1700 in a conformation that facilitates hydrogen bonding of
the Ser1655 hydroxyl group with the phosphate (Figure 1B). To
assesstheimpactoftheT1700Asubstitutiononphosphopeptide
recognition, the ability of this variant to bind a BACH1-derived
peptide was examined using FP spectroscopy (Figure 3A). The
results indicate that the BACH1-derived decapeptide binds to
T1700A with a Kd of 18.9 ( 3.0 μM, a 15-fold reduction
compared to wild type.
To investigate the structural properties that could account for
this signiﬁcant change in peptide binding aﬃnity, the crystal
structure of T1700A was determined at 2.5 Å resolution.
Comparison of this structure with that of the wild-type reveals
onlyaslightreorientationoftheSer1655sidechain;however,the
resolution of this structure is not suﬃcient to assign the orienta-
tion of the Ser1655 hydroxyl (Figure 3B and Figure S1B). To
assess the possible eﬀect on this mutation on Ser1655 hydroxyl
orientation, we carried out molecular dynamic simulations of the
T1700A variant and compared the results to parallel calculations
with the wild-type BRCA1 BRCT, both free and bound to
phosphopeptide. Dynamic properties of the Ser1655 side chain
wereinferredfromaseriesof40000structuralsnapshotstakenat
1 ps intervals along the MD trajectories, and the two serine side-
chaindihedralangles,χ1(N CR Cβ Oγ)andχ2(CR Cβ 
Oγ Hγ), were calculated. The χ1 distributions indicate a very
low ﬂexibility, centered around 190 , which isnotaﬀected bythe
T1700A substitution (Figure S2A). In contrast, major discre-
pancies are observed in the χ2 angular distributions. For simula-
tionsofthewild-typeboundtoaBACH1phosphopeptide,theχ2
angular distribution is centered around þ40 , maintaining
Figure 4. Eﬀect of diﬀerent amino acid substitutions at position 1699
on BRCT structure, stability, and interactions with a BACH1 phospho-
peptide. (A) FP experiments were used to compare the aﬃnity of wild-
type BRCT domain (open squares), the R1699Q (open triangles), and
the R1699W variants (open circles) to bind a BACH1 derived phos-
phopeptide. (B) Comparison of GdmCl denaturation curves of wild-
type BRCT (open squares) and the R1699W variant (ﬁlled squares)
followed by CD spectroscopy monitored at 222 nm. (C) Overlay of
wild-type BRCA1 BRCT domain (cyan, pdb entry 1t15) and the
R1699Q variant (orange). Residues interacting with wild-type
Arg1699 or the variant Gln1699 are represented as sticks as well as
the Phe(þ3) residue of the phosphopeptide. Important hydrogen-
bonding interactions are shown as dashed lines (cyan for wild type,
orange for R1699Q).4585 dx.doi.org/10.1021/bi2003795 |Biochemistry 2011, 50, 4579–4589
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hydrogen bonds with both the phosphate group and Thr1700
throughout the entire simulation (Figure 3C,D and Figure S2B).
For the simulated apo wild-type and T1700A systems, the χ2
values are more dispersed. Two major χ2 orientations are
observed in the wild-type simulation (Figure 3D,E). In one,
the hydrogen atom is oriented toward the peptide binding
groove, similar to the orientation observed in the peptide-bound
simulation (23.3% of total conformations), while in the other, χ2
is between 220  and 280 , orienting the hydroxyl group away
from the phosphate binding pocket and allowing a possible
hydrogen bond with the sulfur atom of Met 1689. The hydrogen
bondbetweenThr1700andSer1655isobservedin46%ofsaved
snapshots (Figure S2C) and correlates with orientation of the
Ser1655 hydroxyl group toward the peptide-binding groove. For
the T1700A system, the Ser1655 Hγ is very rarely oriented
toward the peptide-binding groove (only 3.3% of all simulated
conformations) and is mostly in the opposite direction where it
caninteractwithMet1689(Figure 3F).Thissuggeststhatloss of
the hydrogen bond between Thr1700 and Ser1655 in T1700A
drastically changes the conformational space sampled by the Hγ
diminishingthenumberoforientationscompetentforphosphate
recognition. This may explain the diﬀerence observed in peptide
aﬃnity between the wild-type and the T1700A missense variant.
Analysis of Missense Variants at Position 1699. Arg1699
plays an important role in phosphopeptide recognition through
its interactions with the peptide main chain at the þ3 position
that likely draw the þ3 side chain into the BRCT specificity
pocket (Figure 1B). Interestingly, three missense variants have
been uncovered at this position: R1699L, R1699Q, and
R1699W. Peptide recognition was analyzed for the R1699Q
and R1699W variants with the FP assay (Figure 4A). For the
missense variant R1699Q, the observed Kd value was 28.7 ( 4.1
μM, a 24-fold reduction compared to wild type. For the second
variantR1699W,bindingwasmuchweaker,andtheKdcouldnot
be precisely determined (>200 μM), corresponding to at least a
160-fold reduction in affinity compared to wild type. Similar
results for these variants have been obtained utilizing a different
phosphopeptide in a recent study.
15 Thus, while both variants
display significant defects in phosphopeptide binding affinities,
the R1699W variant appears to be more deleterious.
Limited proteolysis suggested that R1699W is properly
folded;
17however,wenoticedthatthisvarianttendstoaggregate
whenconcentrated, suggesting afolding defectthatmightnotbe
detected by the proteolysis assay. To probe the thermodynamic
stability of this variant, guanidinium hydrochloride (GdmCl)
denaturation proﬁles, monitored with circular dichroism spec-
troscopy(CD)at222nm,werecomparedbetweenR1699Wand
thewild-typeBRCTdomain.Theunusualshapeofthedenatura-
tion curves represented in Figure 4B are similar to those
previously obtained
14,15 and indicate that the BRCT domain
unfolds via an aggregation-prone intermediate. Here, a ﬁrst
transition is observed for the wild type between 1 and 2 M GdmCl
and likely corresponds to the formation of the aggregation-prone
intermediate. This ﬁrst transition is shifted toward lower GdmCl
concentrations for R1699W, suggesting a decreased free energy of
unfolding between the folded state and the intermediate. Around
3 M GdmCl, a second minima is observed, corresponding to the
intermediate. The negative ellipticity is greater for the missense
R1699W, suggesting a more structured intermediate. At higher
GdmCl concentrations, the ellipticity increases as the unfolding of
the intermediate occurs. This transition is shifted toward higher
GdmCl concentrations for the missense R1699W. This would
indicate an increased free energy of unfolding between the inter-
mediate and the unfolded state. Thus, at least part of the binding
defectassociatedwiththeR1699Wmutationislikelyduetoprotein
destabilization. In addition, we predict that the introduction of the
bulky hydrophobic Trp at position 1699 will likely interfere with
dockingofthepeptideþ3positionintotheBRCTpeptide-binding
groove.Unfortunately,wehavenotbeenabletogrowcrystalsofthis
variant of suﬃcient quality for structure determination to directly
visualize any structural changes induced by this substitution.
To uncover the molecular characteristics responsible for the
decrease in peptide binding aﬃnity of the R1699Q variant, the
structure of this variant was determined at 2.8 Å resolution. The
glutamine residue at position 1699 adopts a very similar orientation
to that of the arginine in the wild-type structure (Figure 4C and
FigureS1C).The glutamineside chainispositioned sothattheside
chain NH2 hydrogen bonds with Asp1739 and Asn1742, interac-
tions not observed in the wild-type structure. Because the intro-
duced glutamine is shorter than the arginine side chain, the
interactions with Asp1840 and Glu1836 are lost, and Glu1836
adopts a diﬀerent rotamer in response to the substitution. The
impact of the positioning of Gln1699 is that the side-chain carbonyl
is directed toward the peptide binding cleft, such that it would clash
with the main-chain carbonyl at the peptide þ3 position, providing
an explanation for its decreased peptide aﬃnity.
Figure 5. Functional and structural impact of a charge swap in the
vicinity of Arg1699. (A) Determination of the binding aﬃnities of wild-
type BRCA1 BRCT (open squares) and the E1836K variant (ﬁlled
squares) for a BACH1-derived phosphopeptide using FP. (B) Super-
impositionofwild-typeBRCA1BRCT(pdbcode1t15,orange)andthe
E1836K variant (green), both bound to a BACH1 phosphopeptide.
Residues in the vicinity of the substitution are shown as sticks, and
important hydrogen bonds are represented as dashed lines.4586 dx.doi.org/10.1021/bi2003795 |Biochemistry 2011, 50, 4579–4589
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E1836K:AChargeSwapClosetotheBinding-SiteResidue
R1699. In wild-type BRCA1, the highly conserved residue,
Glu1836, forms a salt bridge with the Arg1699 side chain, likely
helping to position the Arg guanidinium group to bind to the
peptide main chain (Figure 1B). We expected that the Glu-Lys
substitution at this position would therefore impact peptide
binding, and this prediction was tested with the FP assay.
Surprisingly, the Kd of the E1836K variant was 2.0 ( 0.1 μM,
only ∼2-fold reduced compared to wild type. To understand the
molecular binding mode in the variant E1836K, the crystal
structure of this variant complexed with a BACH1-derived
phosphopeptide was determined at 2.85 Å resolution. In three
ofthefourcomplexesinthecrystallographicasymmetricunit,the
introduced lysine side chain could be modeled. A similar con-
formation around the site of substitution is observed in each of
these three complexes that accommodates the charge swap at
position 1836 (Figure 5B and Figure S1E G). In these com-
plexes, Lys1836 is directed away from Arg1699, and the peptide
at position þ4 shifts to accommodate this change (Figure 5B).
The Lys(þ5) side chain of the peptide could not be modeled in
any of the complexes and is likely disordered. This model
provides a molecular basis of peptide binding mode in missense
variant E1836K and reveals how the different positive charges
from the protein and the peptide can be accommodated to
maintain a peptide binding affinity similar to the wild type.
R1835P: Remodeling of the Phe(þ3) Binding Pocket. The
interface between N- and C-terminal BRCT repeats (Figure 1)
forms a largely hydrophobic cleft that recognizes the Phe(þ3)
residue of the peptide. The lower surface is composed of
Met1775, Leu1701, Leu1839, and Phe1704, whereas residues
Asn1774andArg1835definethesideofthispocket(Figure6A).
Mutation of the arginine at position 1835 to proline has been
uncovered from breast cancer screening, and we used the FP
assay to determine the effect of this substitution on peptide
binding (Figure 6B). The R1835P variant exhibits a small but
significant 3-fold decrease in phosphopeptide affinity compared
to wild-type BRCT domain (Kd = 3.6 ( 0.6 μM). To gain
structural insight into this binding defect, the crystal structure of
the R1835P variant was determined at 2.8 Å resolution
(Figure 6C, Figure S1D, and Table 1). The conformational
restriction of the proline at position 1835 leads to a small shift in
the main-chain conformation but is otherwise well accommo-
dated at the N-terminus of R30. The replacement of the long
argininesidechainwiththemorecompactprolineopensoneside
of the Phe recognition pocket and also appears to induce a
conformational change in the R10 β10 loop that is most
significant near Asn1774 (Figure 6C). This partial remodeling
of the hydrophobic pocket may therefore explain the decrease in
peptide affinity observed for the R1835P variant.
’DISCUSSION
Our previous study of the functional consequences of a large
setofBRCA1BRCTvariantsrevealed anintriguingsubsetofthe
variants that were stably folded but nevertheless exhibited
signiﬁcantly reduced function in both peptide binding and tran-
scriptional assays, likely through a direct eﬀect on the phosphopep-
tide binding surface.
17 The phosphopeptide recognition surface of
BRCA1 can be subdivided into two regions: one responsible for
recognition of the target phosphoserine residue and the second
responsibleforrecognitionofthetargetphenylalanineresidueatthe
þ3 position with respect to the phosphoserine. Here we present a
detailed analysis of the structural and functional properties of six
variants that target these speciﬁcr e g i o n s .
Two variants were studied that directly impact the phospho-
serine recognition surface: G1656D and T1700A. Both Gly1656
and Thr1700 are strictly conserved in BRCA1, and it was
therefore surprising that only the T1700A but not the G1656D
mutation reduces peptide-binding aﬃnity. The G1656D muta-
tion introduces a negatively charged residue near the phosphate-
Figure6. AlterationofthehydrophobicPhe(þ3)recognitionpocketin
the R1835P Variant. (A) Close-up view of the Phe(þ3) recognition
pocket of the wild-type BRCA1 BRCT. Residues that comprise the
pocket are shown as sticks with the van der Waals surface in gray. The
phosphopeptide with Phe(þ3) side chain in sticks is displayed in
orange. (B) FP experiments were used to assess the aﬃnity of wild-type
BRCA1 BRCT (open squares) and the R1835P variant (ﬁlled squares)
for the BACH1 phosphopeptide. (C) Close-up view of the Phe(þ3)
recognition pocket in the R1835P variant. Residues that comprise the
pocket are shown as sticks.4587 dx.doi.org/10.1021/bi2003795 |Biochemistry 2011, 50, 4579–4589
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binding pocket that imposes a signiﬁcant decrease in the electro-
static potential at one of the key phosphate ligands, the Ser1655
hydroxyl. While this might be expected to negatively eﬀect phos-
phate binding, recent high-resolution structural studies of S. pombe
Brc1 bound to a target phosphopeptide provide a possible explana-
tion for the phosphopeptide binding activity of this variant.
44
Diﬀerences in the bond lengths between the phosphate oxygens
andtheircoordinatingligandsintheBrc1structureindicatethatthe
phosphate oxygens bound to the mainchain NH and lysine amino
group(positions1656and1702inBRCA1)bearthemajorityofthe
negative charge, while the phosphate oxygen bound to the
serine hydroxyl is predominantly neutral.
44 Such a binding
mode would accommodate a reduction in the electrostatic
potential at the Ser1655 hydroxyl and could therefore explain
the lack of binding defect observed for the G1656D variant.
Nevertheless, the Ser1655 hydroxyl is still a critical binding
ligand, since the shift in its orientation induced by the T1700A
substitution signiﬁcantly reduces binding. Taken together, this
indicates that the Ser1655 hydroxyl group functions primarily
asahydrogen bonddonor inphosphaterecognitionbutthatits
contributions to recognition through an electrostatic eﬀect are
limited.
Several variants were also studied that potentially impact the
þ3speciﬁcity pocket: R1699W,R1699Q, R1835P, and E1836K.
Arg1699 is absolutely conserved in BRCA1 and positions the
peptide þ3 residue in the speciﬁcity pocket through a pair of
hydrogen-bonding interactions. The Arg1699 guanidinium
group binds the peptide main chain carbonyl, while the main
chain carbonyl of Arg1699 binds the main chain NH of the
peptide þ3 residue. The R1699W variant is unable to bind
phosphopeptide, likely due to the perturbation of these interac-
tions, as well as an overall destabilization of the protein fold,
consistent with recent results from other groups.
15 In contrast,
the R1699Q substitution is more conservative and does not
appear to destabilize protein folding to a signiﬁcant degree. It is
able to bind the BACH1 phosphopeptide, albeit with signiﬁ-
cantly reduced aﬃnity, probably due to the loss of hydrogen-
bonding potential between the glutamine side chain and the
peptide backbone. Interestingly, arginine residues are conserved
at analogous positions in other peptide-binding BRCT proteins
such as MDC1, BRC1, Crb2, and the TopBP1 7/8 tandem
repeat, where they contact the peptide backbone at the peptide
þ3 position. The analogous arginine in MDC1 (Arg1933) plays
a particularly important role in the selective recognition of the
phosphorylated tail of γH2AX, where it forms a dual salt bridge
with the peptide C-terminus at the þ3 position.
45 Amidation of
the γH2AX C-terminal carboxylate abrogates MDC1 recogni-
tion, underlining the importance of the dual salt bridge in the
binding process.
46 Likewise, the BRCA1 BRCT domain also
preferentially binds phosphopeptide targets in which the þ3
residue terminates the chain (such as in the double strand break
associated protein, Abraxas).
33 One of the tandem BRCT
domains that does not contain an arginine at this position is
the BRCA1 partner protein, BARD1. While early studies sug-
gested this protein could bind phosphopeptides,
47 more recent
studies have not replicated these initial ﬁndings
48,49 and have
suggested that peptide binding may require elevated pH.
50 The
structure of this tandem BRCT repeat domain reveals a very
similar overall structure to BRCA1, with an intact phosphate
binding pocket, but a serine in place of the conserved arginine,
which would signiﬁcantly impact the way in which this domain
could contact target peptides.
Arg1699 is held in place through salt bridging interactions with
Glu 1836 and Asp 1840 that span the interface between the N- and
C-terminal BRCT repeats and likely stabilize Arg1699 for phos-
phopeptide recognition. Glu1836 is conserved in BRCA1 as well as
MDC1. The E1836K mutation was expected to perturb this
interaction network, and it was therefore surprising that this variant
does not dramatically reduce phosphopeptide binding. The reason
forthisisrevealedinthecrystalstructureofthisvariantboundtothe
BACH1 phosphopeptide, in which Arg1699 remains in place for
interactions with the peptide backbone, likely through its stabilizing
saltbridgetoAsp1840.Thesubstitutedresidue,Lys1836,adoptsan
orientationinwhichitswingsawayfromArg1699,therebyavoiding
a potentially detrimental electrostatic clash.
Theﬁnalvariant,R1835P,directlyaﬀectsthepocketthatbinds
the phenylalanine side chain at the peptide þ3 position. Other well-
studied variants, M1775R and M1775K, disrupt this pocket and are
linked to an increased cancer risk.
19,43 Met1775 occupies the ﬂoor of
this pocket, and its mutation to arginine or lysine leads to a
conformational change so that substituted positively charged side
chain ﬁlls the speciﬁcity pocket, blocking phosphopeptide binding.
Arg1835 is largely conserved in mammalian BRCA1 and forms one
side of the recognition pocket. Mutation of this residue to a proline
essentially removes one face of the recognition pocket and results in
small conformational changes in the vicinity of the pocket. In spite of
these changes, this mutation leads to only a very modest decrease in
peptide binding aﬃnity, suggesting that Arg1835 contributes little to
therecognitionofthepeptideþ3phenylalanine.Bothratandmurine
BRCA1s contain a tryptophan at this position that provides a more
hydrophobic environment for the bound phenylalanine residue.
Takentogether,thisworksuggeststhatthecriticalphosphopeptide
binding surface of BRCA1 can be particularly sensitive to subtle
missensemutations.Interestingly,whilewehavefocusedonmissense
variants that occur in or near this surface, missense substitutions that
occur relatively far from the phosphopeptide binding surface can also
exert subtle conformational eﬀects that signiﬁcantly impact function.
The best-studied example to date is V1809F. Val1809 is positioned
withintheproteinhydrophobiccore,andthestructureoftheV1809F
variant reveals a concerted conformational change in which the large
phenylalanine residue drives the adjacent Leu1780 into a diﬀerent
conformation, which in turn induces a conformational change in
Met1775thatblockstheþ3speciﬁcitypocket.
11Thedetailedanalysis
oftheBRCA1 variantsultimatelycan provideimportantnewinsights
into the functional impact of these variants, which potentially could
help deﬁne the cancer risks associated with these otherwise largely
uncharacterized variants.
’ASSOCIATED CONTENT
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